17038-1-AP
antibody from Proteintech Group
Targeting: CXCL8
3-10C, AMCF-I, b-ENAP, GCP-1, GCP1, IL-8, IL8, K60, LECT, LUCT, LYNAP, MDNCF, MONAP, NAF, NAP-1, NAP1, SCYB8, TSG-1
Antibody data
- Antibody Data
- Antigen structure
- References [9]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 17038-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#17038-1-AP, RRID:AB_2126217
- Product name
- CXCL8/IL-8 antibody
- Antibody type
- Polyclonal
- Description
- CXCL8/IL-8 antibody (Cat. #17038-1-AP) is a rabbit polyclonal antibody that shows reactivity with human and has been validated for the following applications: IHC,ELISA.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references The role of PKM2 nuclear translocation in the constant activation of the NF-κB signaling pathway in cancer-associated fibroblasts.
RIPK3 activation induces TRIM28 derepression in cancer cells and enhances the anti-tumor microenvironment.
MicroRNA-675-3p regulates IL-1β-stimulated human chondrocyte apoptosis and cartilage degradation by targeting GNG5.
LncRNA GUARDIN suppresses cellular senescence through a LRP130-PGC1α-FOXO4-p21-dependent signaling axis.
Interaction with tumor‑associated macrophages promotes PRL‑3‑induced invasion of colorectal cancer cells via MAPK pathway‑induced EMT and NF‑κB signaling‑induced angiogenesis.
Necroptosis promotes cell-autonomous activation of proinflammatory cytokine gene expression.
Radiotherapy induces an immediate inflammatory reaction in malignant glioma: a clinical microdialysis study.
Expression, purification, and characterization of rhTyrRS.
Molecular crosstalk between cancer cells and tumor microenvironment components suggests potential targets for new therapeutic approaches in mobile tongue cancer.
Gu J, Li X, Zhao L, Yang Y, Xue C, Gao Y, Li J, Han Q, Sun Z, Bai C, Zhao RC
Cell death & disease 2021 Mar 17;12(4):291
Cell death & disease 2021 Mar 17;12(4):291
RIPK3 activation induces TRIM28 derepression in cancer cells and enhances the anti-tumor microenvironment.
Park HH, Kim HR, Park SY, Hwang SM, Hong SM, Park S, Kang HC, Morgan MJ, Cha JH, Lee D, Roe JS, Kim YS
Molecular cancer 2021 Aug 21;20(1):107
Molecular cancer 2021 Aug 21;20(1):107
MicroRNA-675-3p regulates IL-1β-stimulated human chondrocyte apoptosis and cartilage degradation by targeting GNG5.
Shen XF, Cheng Y, Dong QR, Zheng MQ
Biochemical and biophysical research communications 2020 Jun 25;527(2):458-465
Biochemical and biophysical research communications 2020 Jun 25;527(2):458-465
LncRNA GUARDIN suppresses cellular senescence through a LRP130-PGC1α-FOXO4-p21-dependent signaling axis.
Sun X, Thorne RF, Zhang XD, He M, Li J, Feng S, Liu X, Wu M
EMBO reports 2020 Apr 3;21(4):e48796
EMBO reports 2020 Apr 3;21(4):e48796
Interaction with tumor‑associated macrophages promotes PRL‑3‑induced invasion of colorectal cancer cells via MAPK pathway‑induced EMT and NF‑κB signaling‑induced angiogenesis.
Zhang T, Liu L, Lai W, Zeng Y, Xu H, Lan Q, Su P, Chu Z
Oncology reports 2019 May;41(5):2790-2802
Oncology reports 2019 May;41(5):2790-2802
Necroptosis promotes cell-autonomous activation of proinflammatory cytokine gene expression.
Zhu K, Liang W, Ma Z, Xu D, Cao S, Lu X, Liu N, Shan B, Qian L, Yuan J
Cell death & disease 2018 May 1;9(5):500
Cell death & disease 2018 May 1;9(5):500
Radiotherapy induces an immediate inflammatory reaction in malignant glioma: a clinical microdialysis study.
Tabatabaei P, Visse E, Bergström P, Brännström T, Siesjö P, Bergenheim AT
Journal of neuro-oncology 2017 Jan;131(1):83-92
Journal of neuro-oncology 2017 Jan;131(1):83-92
Expression, purification, and characterization of rhTyrRS.
Lang Y, Zhang Y, Zhan L, Feng Z, Zhou X, Yu M, Mo W
BMC biotechnology 2014 Jul 15;14:64
BMC biotechnology 2014 Jul 15;14:64
Molecular crosstalk between cancer cells and tumor microenvironment components suggests potential targets for new therapeutic approaches in mobile tongue cancer.
Dayan D, Salo T, Salo S, Nyberg P, Nurmenniemi S, Costea DE, Vered M
Cancer medicine 2012 Oct;1(2):128-40
Cancer medicine 2012 Oct;1(2):128-40
No comments: Submit comment
No validations: Submit validation data